ClearPoint Neuro 2Q 2026: Revenue $10.88M, EPS $(0.38) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.ClearPoint Neuro reported Q2 2026 revenue of $10.88M, an 18% year-over-year increase, driven by a 71% surge in neurosurgery sales. However, the company posted a net loss of $11.34M and a loss per share of $(0.38), widening from the prior year's figures. Year-to-date revenue reached $23.0M. The results reflect continued commercial expansion and operational scaling following the IRRAS integration.
ClearPoint Neuro reported second-quarter 2026 results with revenue rising year over year but wider net losses and a larger loss per share versus the prior-year quarter. Revenue grew to $10.88M, while net loss attributable to stockholders widened to $11.34M and basic and diluted loss per share was $(0.38).
Financial Highlights
- Revenue was $10.88M for Q2 2026, up from $9.215M in the year-ago quarter; YoY change 18%.
- Net income (loss) attributable to stockholders was a loss of $11.337M for Q2 2026, versus a loss of $5.837M in the year-ago quarter (worse YoY).
- Diluted earnings per share: Basic and diluted loss per share of $(0.38) for Q2 2026, versus $(0.21) in the year-ago quarter.
Business Highlights
- Total revenue was up 30% year-to-date to $23.0M, driven by product sales across neurosurgery and capital equipment.
- Neurosurgery revenue jumped 71% YTD, led by IRRAflow sales and adoption of OR navigation software v3.0.
- Biologics services revenue remained steady, supported by a partner base of more than 60 that underpins recurring consulting and preclinical services.
- Commercial expansion continued with increased placements of ClearPoint, IRRAflow control units and Prism lasers, expanding the company’s market footprint.
- Operational scaling following the IRRAS integration expanded commercial and clinical teams and boosted investments in sales, marketing and R&D.
Original SEC Filing: ClearPoint Neuro, Inc. [ CLPT ] - 10-Q - Aug. 03, 2026